Libivirumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Hepatitis B surface antigen |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
569658-79-3  |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6598H10232N1788O2060S46 |
| Molar mass | 149.04 kg/mol |
 (what is this?) (verify) | |
Libivirumab is a human monoclonal antibody directed against the hepatitis B virus.[1][2]
References
- ↑ WHO Drug Information
- ↑ Shouval, D; et al. (2006). "Anti-Viral Effects, Pharmacokinetics and Safety of Two Human Monoclonal Anti-Hbs (Libivirumab/Exbivirumab) Versus Hepatitis B Immune Globulin (Hbig) in Hepatits B Virus (Hbv) in Liver Transplant (Lt) Recipients". Hepatology. 44 (4): 188A–700A [196A]. doi:10.1002/hep.21395. PMID 17001593.
This article is issued from Wikipedia - version of the 8/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.